Advanced ovarian cancer: Criteria of resectability;Quels sont les meilleurs critères d'évaluation de la résécabilité dans les cancers de l'ovaire de stade avancé?

Bulletin du Cancer

Volumn 96, Issue 12, 2009, Pages 1189-1197

  Chereau E ^a   Ballester, M ^a   Rouzier, R ^a   Coutant, C ^a   Darai E ^a  

^a HÔPITAL TENON   (France)

Author keywords

CA 125; Carcinomatosis scores; Complete resection; Ovarian cancer; Resectability

Indexed keywords

CA 125 ANTIGEN;

ADVANCED CANCER; ASCITES; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL EVALUATION; CYTOREDUCTIVE SURGERY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LAPAROSCOPY; LAPAROTOMY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PROGNOSIS; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURGICAL RISK; ADJUVANT THERAPY; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; FEMALE; METHODOLOGY; OVARY TUMOR; PATHOLOGY; PREOPERATIVE CARE;

AREA UNDER CURVE; CA-125 ANTIGEN; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PREOPERATIVE CARE; SENSITIVITY AND SPECIFICITY;

EID: 74049141964     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0985     Document Type: Review

References (45)

1. Morice P, Planchamp F, Daraï E, Leblanc E, Lefranc J, Querleu D, et al. Recommandations pour la pratique clinique : Standards, Options : Recommandations 2007 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l'ovaire. Traitement chirurgical (rapport abrégé). Oncologie 2008 ; 10 : 283-8.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of 326 maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum 327 era: a meta-analysis. J Clin Oncol 2002 ; 20 : 1248-59.
3. Bristow RE. Predicting surgical outcome for advanced ovarian cancer, surgical standards of care and the concept of Kaizen. Gynecol Oncol 2009 ; 112 : 1-3.
4. Gultekin M, Diribas K, Buru E, Dursun P, Yuce K, Ayhan A. Interval debulking in epithelial ovarian carcinomas: the past, present and the future. Eur J Gynecol Oncol 2008 ; 29 : 242-5.
5. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2009 ; CD006014.
6. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 2004 ; 95 : 377-83.
7. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007 ; 104 : 480-90.
8. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status and surgeon. Gynecol Oncol 2006 ; 100 : 33-7 [Epub 2005 Sep 8].
9. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007 ;107 : 99-106.
10. Moore KN, Frank SG, Alward EK, Landrum LM, Myers TK, Walker JL, et al. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer 2009 ; 115: 1472-80.
11. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, et al. Phase II evaluation of nanoparticle albuminbound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal or Fallopian tube cancer. J Clin Oncol 2009 ; 27 : 1426-31 [Epub 2009 Feb 17].
12. Medina-Franco H, García-Alvarez MN, Ortiz-López LJ, Cuairán JZ. Predictors of adverse surgical outcome in the management of malignant bowel obstruction. Rev Invest Clin 2008 ;60 : 212-6.
13. Brockbank EC, Ind TE, Barton DP, Shepherd JH, Gore ME, A'Hern R, et al. Preoperative predictors of sub-optimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 2004 ; 14 : 42-50.
14. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007 ; 99 : 1706-14.
15. Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, et al. Can the preoperative CA-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol. 2009 ; 112 : 11-5.
16. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000 ; 77 : 227-31.
17. de Jong D, Eijkemans MJ, Lie Fong S, Gerestein CG, Kooi GS, Baalbergen A, et al. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology 2007 ; 72 : 293-301.
18. Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predictor of non-optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 2001 ; 80 : 583-5.
19. Saygili U, Guclu S, Uslu T, Erten O, Demir N, Onvural A. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2002 ; 86 : 57-61.
20. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA-125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003 ; 13 : 120-4.
21. Alcázar JL, Miranda D, Unanue A, Novoa E, Alemán S, Madariaga L. CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. Int J Gynecol Obstet. 2004; 84: 173-4.
22. Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest 2004 ; 57 : 153-6.
23. Gemer O, Lurian M, Gdalevich M, Kapustian V, Piura E, Schneider D, et al. A multicenter study of CA-125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 2005 ; 31 : 1006-10.
24. Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA-125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 2006 ; 16 : 496-500.
25. Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC. Preoperative serum CA-125 levels do not predict sub-optimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 2008 ; 18 : 621-8.
26. Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009 ; 112 : 6-10.
27. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993 ; 11 : 166-72.
28. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC. Ovarian carcinoma: value of CT in predicting success of debulking surgery. AJR Am J Roentgenol 1995 ; 165 : 875-8.
29. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000 ; 89 : 1532-40.
30. Byrom J, Widjaja E, Redman CW, Jones PW, Tebby S. Can preoperative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 2002 ; 109 : 369-75.
31. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004 ; 101 : 346-52.
32. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005 ; 96 : 301-6.
33. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007 ; 25 : 384-9.
34. Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/ computed tomography: a prospective study. Gynecol Oncol 2008 ; 108 : 265-70.
35. Gemer O, Gdalevich M, Ravid M, Piura B, Rabinovich A, Gasper T, et al. A multicenter validation of computerized tomography models as predictors of non- optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 2009.
36. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2008 ; 108 : 271-5.
37. Gerestein CG, Damhuis RA, Burger CW, Kooi GS. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol 2009.
38. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006 ; 13 : 1156-61.
39. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 2008 ; 199 : 642.e1-6.
40. Brun JL, Rouzier R, Uzan S, Daraï E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol 2008 ; 110 : 354-9.
41. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995 ; 221 : 124-32.
42. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastro-intestinal cancer. Int Semin Surg Oncol 2005 ; 2 : 3.
43. Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003 ; 29 : 69-73.
44. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003 ; 90 : 390-6.
45. Chéreau E, Ballester M, Selle F, Cortez A, Darai E, Rouzier R. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. AJOG 2009 (in press).